Try Alerts Free   |   Login
Health Care › Industrial Organic Chemicals

CDXS Price Correlated With Financials For Codexis

Free historical financial statements for Codexis Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 41 quarters since 2012. Compare with CDXS stock chart to see long term trends.

CDXS Stock Compared to Quarterly

CDXS Income Statement

Revenue, Net:35340000
Revenue Per Share:0.5412
Cost of Goods & Services Sold:8521000
Selling, General & Admin Expense:15705000
Research & Development Expense:19500000
Total Operating Expenses:43726000
Operating Income:-8386000
Income Taxes:9000
Net Income:-8356000
Earnings Per Share, Basic:-0.13
Shares Outstanding, Basic Avg:65304060

CDXS Cash Flow

Operating Activities Net Income:
Net Cash from Operations:-11186000
Net Cash from Operations Per Share:-0.1713
Net Cash from Financing Activities:-1280000
Property, Plant & Equipment Purchases:5089000
Net Cash from Investing Activities:-10082000
Net Change in Cash & Equivalents:-22548000

CDXS Balance Sheet

Cash and Cash Equivalents:96347000
Accounts Receivable, Net:null
Total Current Assets:144869000
Property, Plant & Equipment, Net:23474000
Total Assets:235274000
Accounts Payable:1949000
Total Short-Term Liabilities:29495000
Total Liabilities:76639000
Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation and Principles of Consolidation

The accompanying consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America ("GAAP") and the applicable rules and regulations of the Securities and Exchange Commission ("SEC") and include the accounts of Codexis, Inc. and its wholly-owned subsidiaries.

Certain prior year amounts have been reclassified in the Consolidated Statements of Cash Flows to conform to the 2021 presentation, however these reclassifications had no effect on the reported results of operations.

The consolidated financial statements include the accounts of Codexis, Inc. and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of our consolidated financial statements in conformity with GAAP requires us to make estimates, judgments and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses and related disclosure of contingent assets and liabilities. We regularly assess these estimates which primarily affect revenue recognition,

inventories, valuation of equity investments, goodwill arising out of business acquisitions, accrued liabilities, stock awards, and the valuation allowances associated with deferred tax assets. Actual results could differ from those estimates and such differences may be material to the consolidated financial statements.

Segment Reporting

We report two business segments, Performance Enzymes and Novel Biotherapeutics, which are based on our operating segments. Operating segments are defined as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker or decision making group (“CODM”), in deciding how to allocate resources, and in assessing performance. Our CODM is our Chief Executive Officer. Our business segments are primarily based on our organizational structure and our operating results as used by our CODM in assessing performance and allocating resources for the Company . We do not allocate or evaluate assets by segment.

The Novel Biotherapeutics segment focuses on new opportunities in the pharmaceutical industry to discover or improve novel biotherapeutic drug candidates that will target human diseases that are in need of improved therapeutic interventions. Similarly, we believe that we can deploy our platform technology to improve specific characteristics of a customer’s pre-existing biotherapeutic drug candidate, such as its activity, stability, or immunogenicity. The Performance Enzymes segment consists of biocatalyst products and services with focus on pharmaceutical, food, molecular diagnostics, and other industrial markets.

Foreign Currency Translation

The USD is the functional currency for our operations outside the United States. Accordingly, non-monetary assets and liabilities originally acquired or assumed in other currencies are recorded in USD at the exchange rates in effect at the date they were acquired or assumed. Monetary assets and liabilities denominated in other currencies are translated into United States dollars at the exchange rates in effect at the balance sheet date. Translation adjustments are recorded in other expense in the consolidated statements of operations. Gains and losses realized from non-USD transactions, including intercompany balances not considered as permanent investments, denominated in currencies other than an entity’s functional currency are included in other expense in the accompanying consolidated statements of operations.

Revenue Recognition

Our revenues are derived primarily from product revenue and collaborative research and development agreements. The majority of our contracts with customers typically contain multiple products and servic

Data imported from Codexis Inc SEC filings. Check original filings before making any investment decision.